Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma
Simeng Hu, … , Fan Bai, Zhi Wang
Simeng Hu, … , Fan Bai, Zhi Wang
Published August 16, 2022
Citation Information: J Clin Invest. 2022;132(19):e157649. https://doi.org/10.1172/JCI157649.
View: Text | PDF
Research Article Immunology Oncology

TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma

  • Text
  • PDF
Abstract

Characterization of the dynamic change in the immunological landscape during malignant transformation from precancerous lesions to cancerous lesions in squamous cell carcinoma (SCC) is critical for the application of immunotherapy. Here, we performed single-cell RNA-Seq (scRNA-Seq) of 131,702 cells from 13 cancerous tissues of oral squamous cell carcinoma (OSCC), 3 samples of precancerous oral leukoplakia, and 8 adjacent normal samples. We found that tumor-infiltrating CD4+ and CD8+ T cells were functionally inhibited by immunosuppressive ligands expressed on various types of myeloid cells or neutrophils in the process of oral carcinogenesis. Notably, we identified a subset of myofibroblasts that exclusively expressed tryptophan 2,3-dioxygenase (TDO2). These TDO2+ myofibroblasts were located distally from tumor nests, and both CD4+ and CD8+ T cells were enriched around them. Functional experiments revealed that TDO2+ myofibroblasts were more likely to possess the ability for chemotaxis toward T cells but induced the transformation of CD4+ T cells into Tregs and caused CD8+ T cell dysfunction. We further showed that use of the TDO2 inhibitor LM10 attenuated the inhibitory states of T cells, restored the T cell antitumor response, and prevented the progression of OSCC malignant transformation in murine models. Our study reveals a multistep transcriptomic landscape of OSCC and demonstrates that TDO2+ myofibroblasts are potential targets for immunotherapy.

Authors

Simeng Hu, Huanzi Lu, Wenqiang Xie, Dikan Wang, Zhongyan Shan, Xudong Xing, Xiang-Ming Wang, Juan Fang, Wei Dong, Wenxiao Dai, Junyi Guo, Yanshu Zhang, Shuqiong Wen, Xin-Yu Guo, Qianming Chen, Fan Bai, Zhi Wang

×

Figure 6

TDO2+ myofibroblasts mediate T cell suppression.

Options: View larger image (or click on image) Download as PowerPoint
TDO2+ myofibroblasts mediate T cell suppression.
(A) Representative imag...
(A) Representative images (Pt14_Ca) (left) and quantitative analyses (right) showing the spatial distribution and the proportions of Foxp3+CD4+ T cells (light blue) around TDO2+ (red) and TDO2– (green) myofibroblasts (radius <50 μm). Scale bars: 50 μm. (B) Representative images (Pt14_Ca) showing the spatial distribution of PD-1+TIM-3+CD8+ T cells around TDO2+ myofibroblasts. Scale bars: 50 μm and 10 μm (enlarged inset). (C) Schematic diagram depicting the coculture strategy for control myofibroblasts (si-NC) and TDO2-knockdown myofibroblasts (si-TDO2) with CD4+ or CD8+ T cells. (D–F) Representative images of flow cytometry (left) and statistical results (right) showing the proportions of (D) Foxp3+CD4+ T cells, (E) PD-1+, and (F) GZMB+CD8+ T cells for the control group (si-NC) and the TDO2-knockdown groups (si-TDO2-1 and si-TDO2-2). (G–I) Representative flow cytometry (left) and statistical results (right) showing the proportion of (G) Foxp3+ T cells, (H) PD-1+, and (I) GZMB+CD8+ T cells after 3 days of coculturing with TDO2– or TDO2+ myofibroblasts or with TDO2+ myofibroblasts plus the TDO2 inhibitor LM10. (J) Representative IHC images of TMAs. The H scores of representative TDO2hi and TDO2lo images were 141.9 and 68.0, respectively. Scale bars: 400 μm (left) and 50 μm (right). (K) OS curve between TDO2hi (n = 71) and TDO2lo (n = 71) cohorts of patients with OSCC according to the staining intensity of IHC images. P < 0.0001, by log-rank test. (A and D–I) *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 1-way ANOVA followed by Bonferroni’s multiple-comparison test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts